Cover Image

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy

Luca Degli Esposti,1 Ennio Giulio Favalli,2 Diego Sangiorgi,1 Roberta Di Turi,3 Giuseppina Farina,4 Marco Gambera,5 Roberto Ravasio,6 1CliCon S.r.l. – Health, Economics & Outcomes Research, Ravenna, 2Department of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, 3Local P...

Full description

Saved in:

Bibliographic Details
Main Authors:	Degli Esposti L (Author), Favalli EG (Author), Sangiorgi D (Author), Di Turi R (Author), Farina G (Author), Gambera M (Author), Ravasio R (Author)
Format:	Book
Published:	Dove Medical Press, 2016-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Assessment of patients affected by rheumatoid arthritis eligible for biotechnological agents and evaluation of their healthcare resource utilization and related costs
by: L. Degli Esposti, et al.
Published: (2021)

Healthcare Resource Consumption and Related Costs of Patients Estimated with Treatment-Resistant Depression in Italy
by: Perrone V, et al.
Published: (2021)

Healthcare resource consumption and cost of care among patients with polycystic kidney disease in Italy
by: Degli Esposti L, et al.
Published: (2017)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
by: Raimondo MG, et al.
Published: (2017)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
by: Crotti C, et al.
Published: (2017)

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
by: Biggioggero M, et al.
Published: (2018)

Costs associated with rheumatoid arthritis in Italy: past, present, and future
by: Benucci M, et al.
Published: (2016)

The social cost of rheumatoid arthritis in Italy: the results of an estimation exercise
by: G. Turchetti, et al.
Published: (2014)

Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting
by: Perrone V, et al.
Published: (2016)

Treatment Pattern Analysis and Health-care Resource Consumption on Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Biological Drugs in a Northern Italian Region
by: Perrone V, et al.
Published: (2020)

Topical medication utilization and health resources consumption in adult patients affected by psoriasis: findings from the analysis of administrative databases of local health units
by: Perrone V, et al.
Published: (2017)

Analysis of disease patterns and cost of treatments for prevention of deep venous thrombosis after total knee or hip replacement: results from the Practice Analysis of THromboprophylaxis after Orthopaedic Surgery (PATHOS) study
by: Degli Esposti L, et al.
Published: (2012)

Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate
by: Benucci M, et al.
Published: (2017)

Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature
by: M. Di Franco, et al.
Published: (2011)

Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)
by: R. Caporali, et al.
Published: (2011)

Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis
by: Marina Amaral de Ávila Machado, et al.
Published: (2016)

Epidemiology, patient profile, and health care resource use for hepatitis C in Italy
by: Sangiorgi D, et al.
Published: (2017)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
by: Ko-Jen Li, et al.
Published: (2021)

Epidemiology, Patients' Journey and Healthcare Costs in Early-Stage Non-Small-Cell Lung Carcinoma: A Real-World Evidence Analysis in Italy
by: Diego Luigi Cortinovis, et al.
Published: (2023)

Indirect costs of the Rheumatoid arthritis in Poland
by: Emilia Howoruszko, et al.
Published: (2019)

Indirect costs of the Rheumatoid arthritis in Poland
by: Emilia Howoruszko, et al.
Published: (2019)

Regional differences of vitamin D deficiency in rheumatoid arthritis patients in Italy
by: M. Rossini, et al.
Published: (2013)

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
by: Degli Esposti L, et al.
Published: (2014)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
by: Vladimira V. Boyadzieva, et al.
Published: (2018)

Switching to an alternative biological agent in juvenile idiopathic arthritis (I)
by: Gonzalez MI, et al.
Published: (2011)

Biological therapy utilization, switching, and cost among patients with psoriasis: retrospective analysis of administrative databases in Southern Italy
by: Guerriero F, et al.
Published: (2017)

Socio-demographic aspects and therapeutic pathways in patients with rheumatoid arthritis in Italy
by: C.M. Montecucco, et al.
Published: (2011)

Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study
by: Perrone V, et al.
Published: (2016)

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry
by: Favalli EG, et al.
Published: (2018)

Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases
by: Degli Esposti L, et al.
Published: (2013)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
by: Martina Biggioggero, et al.
Published: (2019)

Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
by: Cynthia Said, et al.
Published: (2013)

Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain
by: R. Ariza, et al.
Published: (2014)

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
by: Francesco Saverio Mennini, et al.
Published: (2018)

Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study
by: Degli Esposti L, et al.
Published: (2014)

Evaluation of Serum Amyloid A as a Marker of Persistent Inflammation in Patients with Rheumatoid Arthritis
by: Mehmet Agilli, et al.
Published: (2015)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
by: Gianluca Furneri, et al.
Published: (2019)

Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy
by: Degli Esposti L, et al.
Published: (2022)

Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients
by: Rianne Brouwer, et al.
Published: (2022)

Modelling Cost-Effectiveness of Biologic Treatments Based on Disease Activity Scores for the Management of Rheumatoid Arthritis in Spain
by: Ariel Beresniak, et al.
Published: (2011)